Corrigendum to 'Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)' [European Urology Oncology 3 (2021) 256-263]
1 Department of Medical, Oral and Biotechnological Sciences, Laboratory of Biostatistics, University "G. D'Annunzio" Chieti-Pescara, Chieti, Italy; Department of Urology, SS Annunziata Hospital, "G. D'Annunzio" University of Chieti, Chieti, Italy.
2 Department of Urology, University Medical Centre Mannheim, Mannheim, Germany.
3 Department of Urology, Technical University of Munich, Munich, Germany.
4 Department of Urology, School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Turin, Italy.
5 Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
6 Department of Urology, AZ Groeninge, Kortrijk, Belgium.
7 Department of Urology, Hospital La Paz, Madrid, Spain.
8 Department of Urology, Hospital Ramon y Cajal, Madrid, Spain.
9 Department of Urology, Hospital Clinic, Barcelona, Spain.
10 Department of Urology, UC San Diego Moores Cancer Center, University of California San Diego School of Medicine, Louisiana Jolla, CA, USA.
11 Division of Urology, VCU Medical Center, Richmond, VA, USA.
12 Department of Urology, University Hospitals Leuven, Leuven, Belgium.
13 Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy.
14 Department of Urology, University of Verona, AOUI Verona Hospital, Verona, Italy.
15 Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset, Bournemouth, UK.
16 Department of Urology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
17 Department of Urology, Fundacion Instituto Valenciano Oncologia, Valencia, Spain. Electronic address: mirmare@yahoo.es.